The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Bristol Myers Squibb's Breyanzi ® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen...
Takeda and AC Immune have announced an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta...